Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
The world’s most sophisticated drug companies are putting billions into vaccines — despite the political environment
In short
Pharmaceutical leaders continue allocating billions toward vaccine pipelines despite facing a difficult political climate. The heavy spending is driven by clinical advancements that showcase new therapeutic roles for both novel and established shots. Specifically, Moderna and Merck are making strides with an experimental cancer vaccine, while existing shingles immunizations show evidence of potentially delaying dementia onset.
Key points
- Substantial capital continues to flow into vaccine research despite a challenging politic…: Substantial capital continues to flow into vaccine research despite a challenging political environment.
- Technological advancements are expanding the use of immunizations into oncology through e…: Technological advancements are expanding the use of immunizations into oncology through experimental cancer treatments.
- Established inoculations may deliver unexpected medical benefits, including the potential…: Established inoculations may deliver unexpected medical benefits, including the potential to support long-term neurological health.